Marie-Claire Hoyle,a 44-year-old NHS nurse, was denied a state compensation payment after suffering a rare neurological condition during an AstraZeneca vacccine trial. Despite losing the use of her hands, the Vaccine Damage Payment Scheme ruled she did not meet the required 60 per cent disability threshold.
The transverse myelitis that halted the AstraZeneca trials
Marie-Claire Hoyle, who worked with infectious diseases at the Royal Liverpool University Hospital, volunteered for the Oxford University and AstraZeneca vaccine trials in 2020. After receiving her second dose in August 2020, she developed transverse myelitis, a rare neurological condition involving spinal inflammation. This specific side effect was so severe that it led to a worldwide shutdown of the trials while experts investigated the cause.
The condition left Marie-Claire Hoyle unable to use her hands and caused numbness from her collarbone to her thighs. according to the report, an MRI scan later confirmed that her spinal cord remains damaged and will not heal, leaving her with persistent nerve pain in her arm and chest.
The £120,000 payout and the 60 per cent barrier
The Vaccine Damage Payment Scheme (VDPS) offers a one-off payment of £120,000 to individuals who can prove they are at least 60 per cent disabled. Despite her severe symptoms, Marie-Claire Hoyle was denied this payment because she was deemed to fall below that 60 per cent threshold at the time of her application.
Marie-Claire Hoyle described the frustration of this bureaucratic barrier, noting that while she could not hold a pen or a toothbrush at the height of her illness, the state concluded she was no longer disabled enough to qualify for the £120,000. This highlights a systemic issue where the VDPS focuses on current disability levels rather than the peak of the injruy's impact.
Baroness Hallett's push to lower the VDPS threshold
This rigid criteria is currently under scrutiny by Baroness Hallett as part of the Covid-19 Inquiry. Lady Hallett has advocated for reducing the disability threshold to ensure that people with less debilitating, yet still life-altering, injuries can receive compensation. A spokesperson for the Department of Health and Social Care stated that they are carefully considering these recommendations.
The NHS Business Services Authority, which manages the VDPS, maintains that individuals whose claims were refused have the right to challenge the decision and seek a reassessment. However, the current framework remains a point of contention for those who suffered permanent but "sub-threshold" injuries.
Oxford University's five-figure settlement and the gaps in state aid
While the state denied her claim, Marie-Claire Hoyle received a large five-figure sum through a separate out-of-court settlement with Oxford University. As the report notes, Hoyle remains a supporrter of vaccinations, even ensuring her youngest son was vaccinated in 2021, citing the importance of the trials in creating a safe vaccine.
Several questions remain regarding the scale of this issue . It is unclear how many other AstraZeneca trial volunteers were denied VDPS payments due to the 60 per cent rule, and the report does not specify the exact amount of the "five-figure sum" provided by Oxford University. Furthermore, the NHS Business Services Authority has not detailed the success rate of those who challenge their refused claims.
Comments 0